News

Press Releases

China National Medical Products Administration Approves DOPTELET® (avatrombopag) for the Treatment of Thrombocytopenia in Adult Patients with Chronic Liver Disease Who Are Scheduled to Undergo a Procedure 04/30/2020

DURHAM, N.C., April 30, 2020 /PRNewswire/ — AkaRx, Inc., a wholly owned subsidiary of Dova Pharmaceuticals, Inc, a Swedish Orphan Biovitrum AB (publ) (Sobi™) company, today announced DOPTELET® (avatrombopag) has been granted approval from the China National Medical Products Administration (NMPA) for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure (i.e., the CLD indication).

Dova Granted Orphan Drug Designation for Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia 01/13/2020

DURHAM, N.C., Jan. 13, 2020 /PRNewswire/ — Dova Pharmaceuticals, Inc., a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), has been granted Orphan Drug Designation1 (ODD) by the US Food and Drug Administration (FDA) for avatrombopag for the potential treatment of chemotherapy-induced thrombocytopenia (CIT). Enrollment remains ongoing for the phase 3 clinical study of avatrombopag for the treatment of patients with CIT.

Sobi Successfully Completes Acquisition of Dova Pharmaceuticals 11/12/2019

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Dova Pharmaceuticals, Inc. (Dova) (NASDAQ: DOVA) announced today the completion of the acquisition of Dova by Sobi.

Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi) 09/30/2019

DURHAM, N.C., Sept. 30, 2019 (GLOBE NEWSWIRE) — Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) announced today it has entered into an agreement and plan of merger with Swedish Orphan Biovitrum AB (Sobi) (OM:SOBI). Under the terms of the agreement, an indirect subsidiary of Sobi will commence a tender offer for all outstanding shares of Dova, whereby Dova stockholders will be offered an upfront payment for $27.50 per share in cash, along with one non-tradeable Contingent Value Right (CVR) that entitles them to an additional $1.50 per share in cash upon regulatory approval of DOPTELET for the treatment of chemotherapy-induced thrombocytopenia (CIT), representing a total potential consideration of $29.00 per share, or a total potential consideration of up to $915 million on a fully diluted basis.

Dova Pharmaceuticals Announces DOPTELET® (avatrombopag) Now Commercially Available in the United States for Treatment of Chronic Immune Thrombocytopenia (ITP) 07/19/2019

DURHAM, N.C., July 19, 2019 (GLOBE NEWSWIRE) — Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet need, today announced the commercial availability of DOPTELET (avatrombopag) for treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. In June 2019, the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the use of DOPTELET to include this indication.

Dova Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for DOPTELET® (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP) 06/27/2019

DURHAM, N.C., June 27, 2019 (GLOBE NEWSWIRE) — Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet need, today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) that expands the use of DOPTELET (avatrombopag) to include the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Dova Pharmaceuticals Announces European Union Marketing Authorization for DOPTELET® (avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease 06/25/2019

DURHAM, N.C., June 25, 2019 (GLOBE NEWSWIRE) — Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet need, today announced that the European Commission (EC) has granted marketing authorization for DOPTELET® (avatrombopag) for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure.